Straight From The Source: A Live Q&A With The Inventors Of KinetiSol™
In this live Q&A, AustinPx experts Dave A. Miller, PhD, Chris Brough, PhD, and Justin Keen, PhD discuss KinetiSol™ Technology and its role in reimagining amorphous solid dispersion (ASD) development. The conversation explores how KinetiSol’s fusion-based, solvent-free process supports complex molecules, expands formulation design space, and enables a more efficient path from development through commercial manufacturing. The panel also covers technology selection, scale-up, process control, and how earlier ASD strategy can help drug developers reduce risk, improve performance, and prepare for long-term commercial supply.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.